The activity of neuraminidase inhibitor oseltamivir against all subtypes of influenza viruses

Global View of the Fight Against Influenza

Volumn , Issue , 2009, Pages 93-118

  Roberts, Noel A ^a   Govorkova, Elena A ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896410360     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (86)

1. Palmer A and Chambers S. Disease overview-Influenza. Drugs in Context, 2006, 2: 601-648.
2. Wright RF, Neumann G, and Kawaoka Y. Influenza in humans-Past pandemics and the H5N1 epidemic. In: Knipe DM and Howley PM, editors, Fields Virology, Fifth edition, Philadelphia, Lippincott Williams and Wilkins Publishers, 2007, 48: 1697- 1701.
3. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infections with Avian Influenza A (H5N1) Virus. New England J. Med., 2008, 358: 261-273.
4. Palese P and Shaw ML. Orthomyxoviridae: The viruses and their replication. In: Knipe DM and Howley PM, editors, Fields Virology, Fifth edition, Philadelphia, Lippincott Williams and Wilkins Publishers, 2007, 47: 1647-1689.
5. Webster RG, Bean WJ, Gorman OT, Chambers TM, and Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev., 1992, 56 (1): 152-179.
6. Palese P, Zheng H, Engelhardt OG, Pleschka S, and Garcia-Sastre A. Negative-strand RNA viruses: genetic engineering and applications. Proc. Natl. Acad. Sci. USA, 1996, 93: 11354-11358.
7. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, and García-Sastre A. Rescue of influenza A virus from recombinant DNA. J. Virol. 1999, 73: 9679-9682.
8. Claas EC, Osterhaus AD, van Beek R, De Jong J C, Rimmelzwaan GF, Senne D A, Krauss S, Shortridge K F and Webster RG. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet, 1998, 351: 472-477.
9. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, Orr WK, and Shortridge KF. Human infection with influenza H9N2. Lancet, 1999, 354: 916-917.
10. Fouchier RAM, Scneeburger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, Kuiken T, Rimmelzwaan GF, Schutten M, Van Doornum GJ, Koch G, Bosman A, Koopmans M, and Osterhaus AD. Avian influenza A virus (H7N7) associated with conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl. Acad. Sci. USA, 2004, 101: 1356-1361.
11. McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir. Med., 2005, 4(2): 107-116.
12. Aoki FY, Boivin G, Roberts NA. Influenza virus susceptibility and resistance to oseltamivir. Antiviral Therapy, 2007, 12: 603-616.
13. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, and Klenk H-D. Neuraminidase is important for the initiation of influenza infection in human airway epithelium. J. Virol., 2004, 78: 12665-12667.
14. Liu C and Air GM. Selection and characterization of a neuraminidase-minus mutant of influenza virus and its rescue by cloned neuraminidase genes. Virology, 1993, 194(1): 403-407.
15. Hughes MT, Matrosovich M, Rodgers ME, McGregor M, and Kawaoka Y. Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice. J. Virol., 2000, 74: 5206-5212.
16. Coleman PM. Influenza virus neuraminidase: Structure, antibodies, and inhibitors. Protein Science, 1994, 3: 1687-1696.
17. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn MG, Hay AJ, Gamblin SJ, and Skehel JJ. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature, 2006, 443: 45-49.
18. Colman, PM, Varghese JN, and Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature, 1983, 303: 41-44.
19. Gubareva LV, Robinson MJ, Bethell RC, and Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4- guanidino-Neu5Ac2en. J. Virol., 1997, 71: 3385-3390.
20. Chong AKJ, Peggs MS, Taylor NR, and von Itzstein M. Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus. Eur. J. Biochem., 1992, 207: 335-343.
21. Taylor NR and von Itzstein M. Molecular modelling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. J. Med. Chem., 1994, 37: 616-624.
22. Meindl P, Bodo G, Palese P, Schulman J, and Tuppy H. Inhibition of neuraminidase activity by derivatives of 2-Deoxy-2, 3-Dehydro-N-Acetylneuraminic Acid. Virology, 1974, 58: 457-463.
23. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW, Colman PM, Varghese JN, Ryan DM, Woods JM, Bethell RC, Hotham VJ, Cameron JM, and Penn CR. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature, 1993, 363: 418-423.
24. Palese P and Schulman JL. Inhibitors of viral neuraminidase as potential antiviral drugs. In: Oxford JS, editor. Chemoprophylaxis and Virus Infections of the Respiratory Tract, CRC Press, Cleveland, 1977, 6: 189-205.
25. Varghese JN. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins: Structure, Function, and Genetics, 1992, 14: 327-332.
26. Woods JM, Bethell RC, Coates JAV, Healy N, Hiscox SA, Pearson BA, Ryan DM, Ticehurst J, Tilling J, Walcott SM, and Penn CR. 4-Guanidino-2, 4-Dideoxy-2, 3- Dehydro-N-Acetylneuraminic Acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother., 1993, 37: 1473-1479.
27. Ryan DM, Ticehurst J, Dempsey MH, and Penn CR. Inhibition of influenza virus replication in mice by GG167 (4-Guanidino-2, 4-Dideoxy-2, 3-Dehydro-NAcetylneuraminic Acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob. Agents Chemother., 1994, 38: 2270-2275.
28. Ryan DM, Ticehurst J, and Dempsey MH. GG167 (4-Guanidino-2, 4-Dideoxy-2, 3- Dehydro-N-Acetylneuraminic Acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob. Agents Chemother., 1995, 39: 2583-2584.
29. de Jong M, Thanh TT, Khanh TH, Hien VM, Smith GJD, Chau NV, Cam BV, Qui PT, Ha DQ, Guan Y, Peiris JSM, Hien TT, and Farrar J. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N. Engl. J. Med., 2005, 352: 686- 691.
30. Kim CU, Lew W, Williams MA, Liu H, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai CY, Laver WG, and Stevens RC. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Amer. Chem. Soc., 1997, 119: 681-690.
31. Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS, and Mendel DB. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother., 1998, 42: 647-653.
32. Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, Huffman JH, Sweet C, Jakeman KJ, Merson J, Lacy SA, Lew W, Williams MA, Zhang L, Chen MS, Bischofberger N, and Kim CU. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother., 1998, 42: 640-646.
33. He G, Massarella J, and Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet., 1999, 37: 471-484.
34. Eisenberg EJ, Bidgood A, and Cundy KC. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob. Agents Chemother., 1997, 41: 1949- 1952.
35. Roberts NA, Wiltshire HR, Mendel DB, and Webster RG. Oseltamivir carboxylate is effective against all subtypes of influenza neuraminidase. Poster 135, ASM Biodefence Research Meeting, Baltimore, March 2003, http://www.asmbiodefence.org/tuepos.asp.
36. Govorkova EA, Leneva IA, Goloubeva OG, Bush K, and Webster RG. Comparison of efficacies of RWJ-270201, zanamivir and oseltamivir against H5N1, H9N2 and other avian influenza viruses. Antimicrob. Agents Chemother., 2001, 45: 2723-2732.
37. McKimm-Breshkin J, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M, Hayden F, and Zambon M. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isloates to zanamivir and oseltamivir. Antimicrob. Agents Chemother., 2003, 47: 2264-2272.
38. Hurt AC, Barr IG, Durrant CJ, Shaw RP, Sjogren HM, and Hampson AW. Surveillance for neuraminidase inhibitor resistance in influenza viruses from Australia. Commun. Dis. Intell. 2003, 27: 542-547.
39. World Health Organization. September 2008. Updates on avian influenza A (H5N1) infections in man. http://www.who.int/csr/disease/avian_influenza/countrycases_table_2008_09_10/en/index.html.
40. Tumpey TM, Garcia-Sastre A, Mikulasova A, Taubenberger JK, Swayne DE, Palese P, and Basler CF. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc. Natl. Acad. Sci. USA, 2002, 99: 13849-13854.
41. Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, Meijer A, van Steenbergen J, Fouchier R, and Osterhaus A. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet, 2004, 363: 587-593.
42. Meijer A, van de Kamp EEHM, Koch G, and Kimman TG. Cell-ELISA for antiviral susceptibility testing of influenza virus: performance depends on the compatibility of virus strain and type of MDCK cells. Inter. Congr. Series, 2004, 1263: 491-494.
43. Rameix-Welti MA, Agou F, Buchy P, Mardy S, Aubin JT, Veron M, van der Verf S, and Naffakh N. Natural variation can significantly alter sensitivity to oseltamivir of influenza A (H5N1) viruses. Antimicrob. Agents Chemother., 2006, 50: 3809-3815.
44. Saad MD, Boynton BR, Earhart KC, Mansour MM, Niman HL, Elsayed NM, Nayel AL, Abdelghani AS, Essmat HM, Labib EM Ayoub EA, and Monteville MR. Detection of oseltamivir resistance mutations N294S in humans with influenza A H5N1. Options for the Control of Influenza VI, 2007, Toronto, Canada, 228.
45. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, and Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet, 2004, 364: 759-765.
46. McKimm-Breschkin JL, Selleck PW, Usman TB, and Johnson MA. Reduced sensitivity of influenza A (H5N1) viruses. Emerg. Infect. Dis., 2007, 9: 1354-1357.
47. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, Tashiro M, Webster RG, Aymard M, Hayden FG, and Zambon M. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrobial Agents Chemother., 2006, 50: 2395-2402.
48. Sedyaningsih ER, Isfandari S, Setyaway V, Hendroputranto R, and Soendoro T. Clinical features of avian influenza A (H5N1) infections in Indonesia July 2005-April 2007. Options for the Control of Influenza, 2007, Toronto, Canada, 329.
49. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, and Barr IG. Susceptibility of highly pathogenic A (H5N1) avain influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res., 2007, 73: 228-231.
50. Moscona A. Oseltamivir resistance-Disabling our influenza defenses. New Eng. J. Med., 2005, 353: 2633-2636.
51. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, and Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect. Dis., 1998, 178: 1257-1262.
52. Tisdale M. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol., 2000, 10: 45-55.
53. Zambon M and Hayden FG. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res., 2001, 49: 147-156.
54. Matrosovich M, Matrosovich T, Carr J, Roberts NA, and Klenk HD. Overexpression of the a-2,6-sialyltransferase in MDCK cells increases influenza sensitivity to neuraminidase inhibitors. J. Virol., 2003, 77: 8418-8425.
55. Hatakeyama S, Sakai-Tagawa Y Kiso M, Goto H, Kawakami C, Mitamura K, Sugaya Y, and Kawaoka Y. Enhanced expression of an a2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J. Clin. Microbiol., 2005, 43: 4139-4146.
56. Yen HL, Herlocher L, Hoffmann E, Matrosovich MN, Monto AS, Webster RG, and Govorkova EA. Neuraminidase inhibitor-resistant influenza viruses differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother., 2005, 49: 4075-4084.
57. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, and Klenk HD. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc. Nat. Acad. Sci. USA, 2004, 101: 4620-4624.
58. Ilyushina NA, Govorkova EA, Gray TE, Bovin NV, and Webster RG. Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses. PLoS Pathogens, 2008, 4(4): e1000043.
59. Yamanaka T, Tsujimura K, Kondo T, and Matsumura T. In Vitro efficacies of oseltamivir carboxylate and zanamivir against equine influenza viruses. J. Vet. Med. Sci., 2006, 68: 405-408.
60. Scholtissek C, Bürger H, Kistner O, and Shortridge KF. The nucleoprotein as a possible major factor in determining host specificity of influenza H3N2 viruses. Virology, 1985, 147: 287-294.
61. Bauer K, Schrader C, Suess J, Wutzler P, and Schmidtke M. Neuraminidase inhibitor susceptibility of porcine H3N2 influenza viruses isolated in Germany between 1982 and 1999. Antiviral Res., 2007, 75: 219-226.
62. Liu C, Eichelberger MC, Compans RW, and Air GM. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J. Virol., 1995, 69: 1099-1106.
63. Palese P, Tobita K, and Ueda M, Compans RW. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology, 1974, 61: 397- 410.
64. Palese P and Compans RW. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoro-acetyl-neuraminic acid (FANA): mechanism of action. J. Gen. Virol., 1976, 33: 159-63.
65. Ohuchi M, Asaoka N, Sakai T, and Ohuchi R. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect., 2006, 8: 1287-1293.
66. White MR, Crouch E, van Eijk M, Hartshorn M, Pemberton L, Tornoe I, Holmskov U, and Hartshorn KL. Cooperative anti-influenza activities of respiratory innate immune proteins and neuranimidase inhibitor. Am. J. Physiol. Lung Cell Mol. Physiol., 2005, 288: L831-L840.
67. Singh S, Barghoom J, Bagdonas A, Adler J, Treanor J, Kinnersley N, and Ward P. Clinical benefits with oseltamivir in treating influenza in adult populations. Clin. Drug Invest., 2003, 23: 561-569.
68. Ward P, Small I, Smith J, Suter P, and Dutkowski R. Oseltamivir (TamifluR) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother., 2005, 55: 5-21.
69. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, and Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res., 2000, 48 (2): 101-115.
70. Yen HL, Monto AS, Webster RG, and Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J. Infect. Dis., 2005, 192 (4): 665-672.
71. Leigh MW, Connor RJ, Kelm S, Baum LG, and Paulson JC. Receptor specificity of influenza virus influences severity of illness in ferrets. Vaccine, 1995, 13: 1468-1473.
72. Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, and Katz JM. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J. Virol., 2002, 76: 4420-4429.
73. Govorkova EA, Rehg JE, Krauss S, Yen HL, Guan Y, Peiris M, Nguyen TD, Hanh TH, Puthavathana P, Long HT, Buranathai C, Lim W, Webster RG, and Hoffmann E. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J. Virol., 2005, 79: 2191-2198.
74. Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, and Webster RG. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother., 2007, 51: 1414-1424.
75. Boltz DA, Rehg JE, McClaren JL, Webster RG, and Govorkova EA. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model. J. Infect. Dis., 2008, 197: 1315-1323.
76. Gubareva LV, Penn CR, and Webster RG. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-Guanidino-2,4-dideoxy-2,3-dehydro-Nacetylneuraminic acid. Virology, 1995, 212 (2): 323-330.
77. Meijer A, van der Goot JA, Koch G, van Boven M, and Kimman TG. Oseltamivir reduces transmission, morbidity and mortality of highly pathogenic avian influenza in chickens. Inter. Congr. Series, 2004, 1263: 495-498.
78. Ilyushina NA, Bovin NV, Webster RG, and Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res., 2006, 70 (3): 121-131.
79. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, and Govorkova EA. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antiviral Therapy, 2007, 12: 363-370.
80. Ilyushina NA, Hay A, Yilmaz N, Boon ACM, Webster RG, and Govorkova EA. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother., 2008, 52: 3889-3897.
81. Zheng B-J, Chan K-W, Lin Y-P, Zhao G-Y, Chan C, Zhang H-J, Chen H-L, Wong SSY, Lau SKP, Woo PCY, Chan K-H, Jin D-Y, and Yuen K-Y. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc. Natl. Acad. Sci. USA, 2008, 105: 8091-8096.
82. Tweed AS, Skowronski DM, David ST, Larder A, Petric M, Lees W, Li Y, Katz J, Krajden M, Tellier R, Halpert C, Hirst M, Astell, C, Lawrence D, and Mak A. Human illness from avian influenza H7N3, British Columbia. Emerg. Infect. Dis., 2004, 10: 2196-2199.
83. Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, Wat C, Griffiths M, Waalberg E, and Ward P. Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob. Chemother., 2003, 51: 123-129.
84. de Jong MD, Thanh TT, Khanh TH, Hien VM, Smith GJD, Chau NV, Cam BV, Qui PT, Ha DQ, Guan Y, Peiris JSM, Hien TT, and Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. New Engl. J. Med., 2005, 353: 2667-2672.
85. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KHL, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, and Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature, 2005, 437: 1108.
86. Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, and Govorkova EA. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenesis in vitro and in vivo. J. Virol., 2007, 81: 12418-12426.